The discoveries of insulin, insulin pumps, CGMs, and today’s amazing array of oral medications have had major impacts on the lives of people with diabetes. In spite of the availability of these tools to regulate glucose, high A1c levels, glucose variability, and excess hypoglycemia remain all too common. Connectivity is the coming big wave and offers excellent tools to solve these ongoing problems. This advance in health care is being brought about not so much by clinicians or pharmaceutical companies but by telecommunication and software developers. Connectivity is expected to make glucose control more accessible and more affordable with greater clarity for interventions.
A provocative article on the front page of the Sunday’s New York Times (April 6, 2014) took on the high cost of diabetes care and investigated several areas of medical advancements as well as outrageous pricing. The article asks startling questions such as: Are your favorite diabetes drugs and devices relevant to your treatment?
The Asante Snap began to ship in April of 2013, two years after receiving FDA approval. The Snap is being rolled out by region, starting in the Northeast US, with gradual availability to other regions. This allows Asante to build up their sales and service network (Similar to Insulet’s rollout of the Omnipod). Asante has focused on ease of pump use and highlights how easy it is to use the Snap pump and change out the cartridge, among other things.
Who does your diabetes data belong to? You - obviously. You're the one who created it and needs it for diabetes management. Your glucose readings, your insulin doses, your carbs and meals consumed, your exercise events, your stress levels, your devices. How can you take charge of your data and benefit from it?
The FDA approved the Medtronic MiniMed 530G insulin pump with its display of the Enlite continuous glucose monitor in September, 2013. The 530G is the first system in the United States that can automatically stop insulin delivery if the CGM's glucose value falls to a preset level (60-90 mg/dl) AND the wearer doesn't respond to the Threshold Suspend Alarm. This functionality puts the device in the newly created OZO: Artificial Pancreas Device Classification created by the U.S. Food and Drug Administration.
The Animas Vibe is an insulin pump with a built in Dexcom Continuous Glucose Monitor. Although there is a pump-only version of the Vibe available, the combination of the pump and monitor are what makes the Vibe stand out. The Vibe, alone, is basically the Animas 2020 pump platform from a few years ago.
The Vibe has been available in the UK since 2011. Johnson & Johnson finally submitted the Animas Vibe to the FDA in April of 2013.
The APP Study was conducted to see how people who have good control really use their pumps and to find what settings give the best glucose results. We analyzed anonymous data from several hundred Deltec Cozmo insulin pumps (Smiths Medical) that were consecutively downloaded during a large, routine software upgrade of all Cozmo pumps in 2007. The pumps were prescribed and used around the U.S. by a wide variety of clinicians and wearers. Insulin dosing was analyzed from a subset of 396 pumps where glucose readings were directly entered from an attached meter.